RxDoctor Payments Data

Andrew Barger

Gerontology · Austin, TXNPI 1134538978

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $18,446 of the $21,771 with a category attached, or 84.7%. Teleflex LLC accounts for 94.6% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2021 at $18,360 and has fallen 96.0% since, to $728 in 2025. Among gerontology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,771in general payments, 2019–2025

Across 119 payments — averaging $182.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$21K
  • Olympus America Inc.$471
  • Boston Scientific$257
  • Astellas Pharma US Inc$168
  • Axonics, Inc.$119
  • Sumitomo Pharma America, Inc.$50
  • plus $101 from 5 others

What the payments were for

  • Consulting fees$3302%
  • Speaking & faculty fees$18,44685%
  • Travel & lodging$1,0075%
  • Food & beverage$1,8208%
  • Education$1681%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,771 in reported general payments places this provider in the 95th percentile of 653 gerontology providers in Texas.

See all gerontology providers in Texas

Medicare billing

Part B allowed, 2024
$34,824
Medicare patients
283
Services billed
467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron41$29,590
GemtesaVibegron25$17,067
Tamsulosin Hcl586$9,690
Testosterone Cypionate92$4,780
Testosterone25$4,776
Mirabegron ErMirabegron11$3,000
Estradiol29$2,728
Silodosin11$2,054
Alfuzosin Hcl ErAlfuzosin Hcl85$1,878
Finasteride153$1,863
Potassium Citrate ErPotassium Citrate17$1,683
Solifenacin Succinate19$1,604
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst21$1,487
NitrofurantoinNitrofurantoin Macrocrystal22$1,296
Trimethoprim15$1,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$168$29,59041 claims
Sumitomo Pharma America, Inc.Gemtesa$50$17,06725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 gerontology providers in Texas.

Other gerontology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →